ADC Therapeutics (ADCT) Jefferies 2024 Global Healthcare Conference summary

Portfolio overview and strategy

• Focused on antibody-drug conjugates with an approved hematology product and a robust early-stage solid tumor pipeline.

• Cash runway extends to mid-2026, supporting multiple catalysts through 2025.

• Portfolio split between hematology (ZYNLONTA, ADCT-602) and solid tumors (ADCT-601, exatecan-based candidates).

• Capital allocation prioritizes hematology for near-term profitability, with solid tumor assets aimed for partnerships.

Hematology pipeline and clinical progress

• ZYNLONTA approved for third-line plus DLBCL, with expansion opportunities in earlier DLBCL lines and indolent lymphomas.

• LOTIS-5 (ZYNLONTA + rituximab) pivotal phase 3 study to complete enrollment by year-end, readout expected late 2025, potential approval late 2026.

• LOTIS-7 (ZYNLONTA + glofitamab/mosunetuzumab) phase 1 dose escalation completed with no DLTs; dose expansion ongoing, 40 patients to be enrolled by year-end.

• Early data in high-risk follicular lymphoma (96% ORR, 85% CR) and marginal zone lymphoma (13/15 CRs) show strong efficacy and durability.

• IITs in follicular and marginal zone lymphomas target regulatory and guideline inclusion with 100- and 50-patient studies, respectively.

Market landscape and unmet needs

• DLBCL frontline care dominated by R-CHOP/Polivy; CAR T used in second line for academic centers, but access limited in community settings.

• CAR T achieves ~70% CR, other therapies ~40% CR, leaving 80% of patients with significant unmet need.

• Bispecifics gaining share post-CAR T in academic centers, but limited community access.

• Indolent lymphoma regimens have low CR rates (~29%), and BTK inhibitors require prolonged treatment, creating demand for fixed-duration, high-efficacy options.